Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in the discovery, development, manufacturing and marketing of pharmaceutical products. The company is best known for its leadership in diabetes care, offering a broad portfolio of insulin analogs, oral antidiabetic agents and injectable treatments designed to help patients manage blood glucose levels effectively. With a presence in over 80 countries, Novo Nordisk serves millions of people living with chronic conditions and strives to improve health outcomes through innovative therapies.
Beyond its core diabetes franchise, Novo Nordisk has expanded into related therapeutic areas including obesity management, haemophilia care, growth hormone therapy and hormone replacement therapy. Key brands include long-acting and rapid-acting insulin analogs, GLP-1 receptor agonists for weight management and blood sugar control, and recombinant clotting factors for patients with bleeding disorders. The company also invests heavily in next-generation modalities such as oral peptide formulations, advanced drug delivery systems and digital health solutions to support patient adherence and real-world data collection.
The company’s origins can be traced to the pioneering work of Nobel Prize laureate August Krogh and his wife Marie Krogh, who facilitated the first production of insulin in Denmark. Novo Nordisk emerged in 1989 through the merger of Novo Industri A/S and Nordisk Gentofte A/S, combining decades of expertise in industrial biotechnology and clinical research. Over the years, the organization has built a comprehensive global manufacturing network and established partnerships with academic institutions and technology companies to accelerate innovation and ensure quality supply to patients worldwide.
Under the leadership of President and CEO Lars Fruergaard Jørgensen, Novo Nordisk has prioritized long-term sustainability, patient access and digital transformation. The executive team focuses on strengthening the company’s pipeline through strategic alliances in gene and cell therapy, as well as fostering a culture of scientific rigor and corporate responsibility. With a commitment to tackling serious chronic diseases, Novo Nordisk continues to pursue ambitious research goals aimed at delivering transformational treatments and improving health equity on a global scale.
